Technology
Health
Medical

Hancock Jaffe

$2.40
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.42%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Hancock Jaffe and other stocks, options, ETFs, and crypto commission-free!

About

Hancock Jaffe Laboratories, Inc. Common Stock, also called Hancock Jaffe, is a development stage medical device company, which develops biologic-based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Read More Its products include The Bioprosthetic Heart Valve, The CoreoGraft, and The Venous Valve. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

Employees
Headquarters
Irvine, California
Founded
1999
Market Cap
28.02M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
110.81K
High Today
$2.49
Low Today
$2.32
Open Price
$2.37
Volume
42.79K
52 Week High
$5.64
52 Week Low
$1.31

Collections

Technology
Health
Medical
2017 IPO
US
North America

News

MarketBeatMar 3

Stock Price, News, & Analysis for Hancock Jaffe Laboratories

Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prost...

77
Markets InsiderFeb 19

Hancock Jaffe Successfully Starts First-in-Human VenoValve Study

IRVINE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced the successful start of its VenoValve® first-in-human study in Bogota, Colombia. The first VenoValve was implanted in a patient and the procedure went very well. The patient was walking the day after the surgery, the VenoValve appears to be functioning as it should, and the patient shows no early signs of...

222

Earnings

-$1.06
-$0.75
-$0.44
-$0.13
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 25, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.